Tempered Enthusiasm for Fecal Transplant
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
To theEditor—The attraction of fecal microbiota transplant (FMT) as a treatment for Clostridium difficile infection (CDI) is based on reported efficacy and safety [1, 2]. At our institution, we had used FMT in 10 refractory cases without complication. Our most recent FMT has tempered our enthusiasm. A 68-year-old man with advanced oropharyngeal cancer necessitating gastric tube (G-tube) feeding, diabetes mellitus, and coronary artery disease was treated twice in the preceding 6 months at another institution for severe CDI. His first episode had been complicated by shock and was treated with intravenous metronidazole, fidaxomicin, and a prolonged taper of vancomycin. Subsequently, he relapsed with C. difficile–associated septic shock (toxin positive, pseudomembranes). This second life-threatening C. difficile episode was treated with intravenous metronidazole and tigecycline as well as fidaxomicin. After 18 days, the patient transferred to our hospital for FMT. On arrival he was afebrile, hemodynamically stable, and in no distress, but was having frequent loose stools. His abdomen was moderately distended without tenderness; anasarca was noted. A G-tube was in place. His white blood cell (WBC) count was 9.7 × 103/µL, creatinine level was 1.4 mg/dL, and stool C. difficile polymerase chain reaction (Cephacid) was positive. Abdominal computed tomography (CT) demonstrated diffuse pancolitis without dilatation. He was receiving fidaxomicin via G-tube and intravenous metronidazole. After obtaining consent from the patient, we proceeded with FMT. The spouse served as the donor. As per our protocol, she was screened for human immunodeficiency virus, hepatitis A, B, and C viruses, cytomegalovirus, and C. difficile. Sixty grams of donor stool was mixed with 70 mL of saline, filtered twice, and infused via a gastrojejunostomy tube placed through the G-tube. The position of the tip of the gastrojejunostomy tube near the ligament of Treitz was confirmed by contrast injection under fluoroscopy and routine abdominal radiography just prior to the fecal instillation. The procedure itself was uncomplicated, and all antimicrobials were stopped after the FMT. During the first 48 hours after FMT, the patient had no abdominal pain, he was afebrile and hemodynamically stable, and his stools were “thicker” than before FMT. Early on the third day after FMT, the patient noted recurrent abdominal pain. He was newly hypotensive (blood pressure 68/41 mm Hg), tachycardic (140 beats per minute), and tachypneic (28 breaths per minute). His WBC count was 600 × 103/µL, and blood cultures grew Pseudomonas aeruginosa, Escherichia coli, and Lactobacillus casei. A CT scan revealed a dilated colon (10 cm) and pneumoperitoneum. During an emergent surgical procedure, it was found that the G-tube was dislodged, producing the free air; there was no bowel perforation or overt peritonitis. The massively dilated colon was resected, but the patient's septic shock proved refractory to aggressive intensive care and he died on the fourth day after FMT. One of the selling points of FMT for refractory CDI has been its safety. To our knowledge, only a single case of attributable death (due to aspiration pneumonia) has been reported after FMT [3]. Our patient decompensated with toxic megacolon and shock 48 hours after FMT. The reason for this precipitous decline is unclear. Perhaps the abrupt discontinuation of C. difficile therapy after FMT contributed, but to continue antimicrobials after FMT seemed counterintuitive. Following this death, we have modified our FMT consent form to include the possibility of catastrophic post-FMT colitis, sepsis, and death. Potential conflicts of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fecal microbiota transplantation: a practical update for the infectious disease specialist
Moore, T., Rodriguez, A., & Bakken, J. S. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/cit950 · Cited by 69
Cited by
Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant
DeFilipp, Z., Bloom, P. P., Torres Soto, M., Mansour, M. K., Sater, M. R. A., Huntley, M. H., Turbett, S., Chung, R. T., Chen, Y.-B., & Hohmann, E. L. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910437 · Cited by 1,281
European consensus conference on faecal microbiota transplantation in clinical practice
Cammarota, G., Ianiro, G., Tilg, H., Rajilić-Stojanović, M., Kump, P., Satokari, R., Sokol, H., Arkkila, P., Pintus, C., Hart, A., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-313017 · Cited by 1,207
“The implementation of registry data collections can effectively deal the issue of long-term monitoring of patients for adverse events.”
BackgroundShen, Z.-H., Zhu, C.-X., Quan, Y.-S., Yang, Z.-Y., Wu, S., Luo, W.-W., Tan, B., & Wang, X.-Y. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i1.5 · Cited by 646
Fecal Microbiota Transplantation for Clostridium difficile Infection: A Systematic Review
Drekonja, D., Reich, J., Gezahegn, S., Greer, N., Shaukat, A., MacDonald, R., Rutks, I., & Wilt, T. J. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2693 · Cited by 371
Orenstein, R., Dubberke, E., Hardi, R., Ray, A., Mullane, K., Pardi, D. S., & Ramesh, M. S. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ938 · Cited by 197
“Case reports have cited hypotension [20], herpes zoster [21], Escherichia coli bacteremia [22], flares of ulcerative colitis [23], norovirus transmission [24], and significant weight Table 1.”
Background
Metadata
- Authors
- Solari, P. R., Fairchild, P. G., Noa, L. J., & Wallace, M. R.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-04-23
- Volume
- 59
- Issue
- 2
- Pages
- 319-319
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2093207028
- Cited by
- 72
- References
- 1
- FWCI
- 6.49
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.